Autologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia Ishida Akio Ohya Yusuke Sakuda Hitoshi Ohshiro Katsuhiko Higashiuesato Yasushi Nakaema Moriyasu Matsubara Shinobu Yakabi Shizuko Kakihana Ayano Ueda Mika Miyagi Chiharu Yamane Nobuhisa Koja Kageharu Komori Kimihiro Takishita Shuichi 社団法人日本循環器学会 Circulation Journal 13469843 69 10 1260 1265 2005-09-20 Background Implantation of bone marrow mononuclear cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous peripheral blood mononuclear cells (PBMNCs) implantation after granulocyte-colony stimulating factor (G-CSF)-induced mobilization was investigated in patients with severe peripheral arterial disease. Methods and Results Six cases were enrolled : 5 of thromboangitis obliterans and 1 of arteriosclerosis obliterans. Following administration of G-CSF (10μg・kg^<-1>・day^<-1>), PBMNCs were harvested and injected intramuscularly (5 legs and 1 arm) for 2 days for the patients with ischemia of the legs. No serious adverse events related to G-CSF administration, harvest or implantation were observed during this study period. Improvement in the ankle-brachial pressure index (ΔABI : >0.1) was seen in 4 patients at 4 weeks and ischemic ulcers improved in 3 of 3 patients. The mean maximum walking distance significantly increased from 203m to 559m (p=0.031) at 4 weeks and was sustained for 24 weeks. Significant improvement was seen in physiological functioning subscale of Short Form-36. Conclusion Implantation of PBMNCs collected after G-CSF administration could be an alternative to therapeutic angioplasty in patients with severe peripheral arterial disease. 2005-09-20 110002703877 AA11591968 ENG CJPref NII-ELS J-STAGE 3 11 Autologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia Ishida Akio Ohya Yusuke Sakuda Hitoshi Ohshiro Katsuhiko Higashiuesato Yasushi Nakaema Moriyasu Matsubara Shinobu Yakabi Shizuko Kakihana Ayano Ueda Mika Miyagi Chiharu Yamane Nobuhisa Koja Kageharu Komori Kimihiro Takishita Shuichi Japanese Circulation Society Circulation journal : official journal of the Japanese Circulation Society Background Implantation of bone marrow mononuclear cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous peripheral blood mononuclear cells (PBMNCs) implantation after granulocyte-colony stimulating factor (G-CSF)-induced mobilization was investigated in patients with severe peripheral arterial disease. Methods and Results Six cases were enrolled : 5 of thromboangitis obliterans and 1 of arteriosclerosis obliterans. Following administration of G-CSF (10μg・kg^<-1>・day^<-1>), PBMNCs were harvested and injected intramuscularly (5 legs and 1 arm) for 2 days for the patients with ischemia of the legs. No serious adverse events related to G-CSF administration, harvest or implantation were observed during this study period. Improvement in the ankle-brachial pressure index (ΔABI : >0.1) was seen in 4 patients at 4 weeks and ischemic ulcers improved in 3 of 3 patients. The mean maximum walking distance significantly increased from 203m to 559m (p=0.031) at 4 weeks and was sustained for 24 weeks. Significant improvement was seen in physiological functioning subscale of Short Form-36. Conclusion Implantation of PBMNCs collected after G-CSF administration could be an alternative to therapeutic angioplasty in patients with severe peripheral arterial disease. Ishida Akio Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine Ohya Yusuke Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine Sakuda Hitoshi Second Department of Surgery, University of the Ryukyus School of Medicine Ohshiro Katsuhiko Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine Higashiuesato Yasushi Department of Clinical Laboratories, University of the Ryukyus School of Medicine Nakaema Moriyasu Second Department of Surgery, University of the Ryukyus School of Medicine Matsubara Shinobu Second Department of Surgery, University of the Ryukyus School of Medicine Yakabi Shizuko Blood Transfusion Department, University of the Ryukyus School of Medicine Kakihana Ayano Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine Ueda Mika Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine Miyagi Chiharu Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine Yamane Nobuhisa Blood Transfusion Department, University of the Ryukyus School of Medicine Koja Kageharu Second Department of Surgery, University of the Ryukyus School of Medicine Komori Kimihiro Division of Vascular Surgery, Department of Surgery, Nagoya University, Graduate School of Medicine Takishita Shuichi Division of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine